{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:53:05Z","timestamp":1703159585222},"reference-count":20,"publisher":"Akademiai Kiado Zrt.","issue":"36","license":[{"start":{"date-parts":[[2021,9,5]],"date-time":"2021-09-05T00:00:00Z","timestamp":1630800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,9,5]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> A hiperakt\u00edv h\u00fagyh\u00f3lyag szindr\u00f3ma n\u00e9pbetegs\u00e9g\n                    m\u00e9rt\u00e9k\u0171 probl\u00e9ma, mely jelent\u0151sen rontja az \u00e9rintettek \u00e9letmin\u0151s\u00e9g\u00e9t. A\n                    konzervat\u00edv, gy\u00f3gyszeres kezel\u00e9s eredm\u00e9nytelens\u00e9ge eset\u00e9n m\u00e1sodvonalbeli\n                    ter\u00e1piak\u00e9nt a minim\u00e1lisan invaz\u00edv botulinumtoxin intradetrusor injekci\u00f3\n                    javasolhat\u00f3. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> A nem neurog\u00e9n eredet\u0171 hiperakt\u00edv\n                    (t\u00falm\u0171k\u00f6d\u0151) h\u00f3lyag szindr\u00f3ma miatt v\u00e9gzett botulinumtoxin intradetrusor\n                    injekci\u00f3s kezel\u00e9s hat\u00e9konys\u00e1g\u00e1nak, biztons\u00e1goss\u00e1g\u00e1nak felm\u00e9r\u00e9se saj\u00e1t\n                    beteganyagunkon, \u00e9s annak vizsg\u00e1lata, hogy az eredm\u00e9nyess\u00e9get befoly\u00e1solj\u00e1k-e a\n                    vizsg\u00e1lt preoperat\u00edv param\u00e9terek. <jats:italic>M\u00f3dszer:<\/jats:italic> Egy retrospekt\u00edv\n                    vizsg\u00e1lat sor\u00e1n \u00f6sszegy\u0171jt\u00f6tt\u00fck 33, intradetrusor BOTOX<jats:sup>\u00ae<\/jats:sup> injekci\u00f3n\n                    \u00e1tesett beteg\u00fcnk perioperat\u00edv adatait (\u00e9letkor, testt\u00f6megindex, k\u00eds\u00e9r\u0151\n                    betegs\u00e9gek, anat\u00f3miai elt\u00e9r\u00e9sek, kor\u00e1bbi m\u0171t\u00e9tek, panaszok, urodin\u00e1mi\u00e1s\n                    leletek). Az eredm\u00e9nyess\u00e9g \u00e9s a posztoperat\u00edv komplik\u00e1ci\u00f3k felm\u00e9r\u00e9se a\n                    betegdokument\u00e1ci\u00f3, telefoninterj\u00fak, k\u00e9rd\u0151\u00edvek seg\u00edts\u00e9g\u00e9vel t\u00f6rt\u00e9nt. A\n                    statisztikai anal\u00edzis sor\u00e1n kapott eredm\u00e9nyeket p&lt;0,05 eset\u00e9n tekintett\u00fck\n                    szignifik\u00e1nsnak. <jats:italic>Eredm\u00e9nyek:<\/jats:italic> M\u0171t\u00e9t ut\u00e1n jelent\u0151s sz\u00f6v\u0151dm\u00e9nyt\n                    nem tapasztaltunk (p&gt;0,05), 6 betegn\u00e9l \u00e9szlelt\u00fcnk h\u00f3lyagkat\u00e9terez\u00e9st nem\n                    ig\u00e9nyl\u0151 residuumot (p = 0,024). Az urgencia, \u2019urge\u2019 incontinentia, pollakisuria,\n                    nycturia el\u0151fordul\u00e1sa \u00e9s m\u00e9rt\u00e9ke, a vizeletincontinentia miatti bet\u00e9thaszn\u00e1lat\n                    szignifik\u00e1nsan cs\u00f6kkent (p&lt;0,01), az \u00e9letmin\u0151s\u00e9g, az \u00e1ltal\u00e1nos eg\u00e9szs\u00e9gi\n                    \u00e1llapot mutat\u00f3i szignifik\u00e1nsan javultak a m\u0171t\u00e9t ut\u00e1n (p&lt;0,001). A\n                    perioperat\u00edv faktorok \u00e9s a posztoperat\u00edv eredm\u00e9nyess\u00e9g (72,7%) k\u00f6z\u00f6tt\n                    szignifik\u00e1ns kapcsolat nem igazol\u00f3dott (p&gt;0,05).\n                        <jats:italic>Megbesz\u00e9l\u00e9s:<\/jats:italic> A t\u00fcneti javul\u00e1s eredm\u00e9nyei megegyeznek az\n                    irodalmi adatokkal, a nemzetk\u00f6zi publik\u00e1ci\u00f3kban k\u00f6z\u00f6lt eredm\u00e9nyekhez k\u00e9pest is\n                    jobb mell\u00e9khat\u00e1sprofil pedig az \u00f3vatosabb betegszelekci\u00f3val \u00e9s r\u00e9szletesebb\n                    kivizsg\u00e1l\u00e1ssal magyar\u00e1zhat\u00f3. <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> A\n                    botulinumtoxin-A-ter\u00e1pia hat\u00e9kony, biztons\u00e1gos, minim\u00e1lisan invaz\u00edv kezel\u00e9se a\n                    ter\u00e1piarefrakter hiperakt\u00edv h\u00f3lyag szindr\u00f3m\u00e1nak. Nem siker\u00fclt olyan preoperat\u00edv\n                    faktort azonos\u00edtanunk, mely szignifik\u00e1ns hat\u00e1ssal b\u00edrna a kezel\u00e9s\n                    eredm\u00e9nyess\u00e9g\u00e9nek el\u0151rejelz\u00e9s\u00e9re. Orv Hetil. 2021; 162(36): 1459\u20131465.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> Overactive bladder syndrome is an endemic\n                    phenomenon, which has a significant impact on the quality of life. In cases\n                    where conservative treatment fails, intradetrusor onabotulinumtoxinA injection\n                    can be used as second-line therapy. <jats:italic>Objective:<\/jats:italic> To assess the\n                    safety and efficacy of onabotulinumtoxinA treatment in the management of\n                    non-neurogenic detrusor overactivity among our patients. Also, to examine the\n                    influence of perioperative factors on the effects of the efficacy.\n                        <jats:italic>Method:<\/jats:italic> We have retrospectively collected the perioperative\n                    data of 33 patients treated with intradetrusor BOTOX<jats:sup>\u00ae<\/jats:sup>. The assessment\n                    of the efficacy and complications was done by the examination of patient files\n                    and questionnaires. The results obtained during the statistical analysis were\n                    considered significant for p&lt;0.05. <jats:italic>Results:<\/jats:italic> We have not\n                    experienced notable complications after the procedures. Only 6 patients had\n                    residual urine (p = 0.024), none of them needed to be catheterized. We have\n                    observed significant decrease in the incidence of frequency, nocturia, urgency\n                    and incontinence, just as in the number of pads needed daily (p&lt;0.01).\n                    Quality of life and general health were significantly improved (p&lt;0.001). We\n                    have not found any significant connection between preoperative factors and\n                    efficacy (72.7%). <jats:italic>Discussion:<\/jats:italic> Our results considering the\n                    relief of symptoms are well in line with international data. The fact that our\n                    rate of complications is \u2013 in international comparison \u2013 outstanding can be\n                    explained by a more careful patient selection and thorough preoperative\n                    assessment. <jats:italic>Conclusion:<\/jats:italic> OnabotulinumtoxinA therapy is a safe\n                    and effective solution of therapy-refractory overactive bladder. We could not\n                    identify any perioperative factor to predict postoperative efficacy of therapy.\n                    Orv Hetil. 2021; 162(36): 1459\u20131465.<\/jats:p>","DOI":"10.1556\/650.2021.32288","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T01:08:41Z","timestamp":1633914521000},"page":"1459-1465","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["Hiperakt\u00edv (t\u00falm\u0171k\u00f6d\u0151) h\u00fagyh\u00f3lyag kezel\u00e9se botulinumtoxin-A-ter\u00e1pi\u00e1val"],"prefix":"10.1556","volume":"162","author":[{"given":"Attila","family":"Majoros","sequence":"first","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Romics","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Ali","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antal","family":"Hamvas","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter J\u00f3zsef","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Keszthelyi","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Urol\u00f3giai Klinika \u00e9s Uroonkol\u00f3giai Centrum, Budapest, \u00dcll\u0151i \u00fat 78\/b, 1082"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 Abrams P, Cardozo L, Wagg A, et al. (eds.) Incontinence. 6th Edition 2017. 6th International Consultation on Incontinence, Tokyo, September, 2016. ISBN: 978-0-9569607-33."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"2 Milsom","year":"2001","unstructured":"2 Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87: 760-766.","journal-title":"BJU Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"3 Irwin","year":"2006","unstructured":"3 Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50: 1306-1314.","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"4 Reeves","year":"2006","unstructured":"4 Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol. 2006; 50: 1050-1057.","journal-title":"Eur Urol"},{"key":"ref4","unstructured":"5 Professional guidelines of the Ministry of Human Resources on non-neurogenic urinary incontinence in adulthood. [Az Emberi Er\u0151forr\u00e1sok Miniszt\u00e9riuma szakmai ir\u00e1nyelve a feln\u0151ttkorban el\u0151fordul\u00f3, nem neurog\u00e9n eredet\u0171 vizeletinkontinenci\u00e1r\u00f3l.] E\u00fc K\u00f6zl. 2016; LXV(6): 1180-1200. [Hungarian]"},{"key":"ref5","unstructured":"6 Burkhard FC, Bosch JL, Cruz F, et al. European Association of Urology (EAU) guidelines: urinary incontinence. 2020. Available from: https:\/\/uroweb.org\/guideline\/urinary-incontinence [accessed: April 15, 2021]."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Dhaliwal P, Wagg A. Overactive bladder: strategies to ensure treatment compliance and adherence. Clin Interv Aging 2016; 11: 755-760.","DOI":"10.2147\/CIA.S69636"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8 Kozma, B. Majoros A, Pytel \u00c1, et al. Efficacy of the percutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms. [A percutan nervus tibialis stimul\u00e1ci\u00f3 szerepe egyes kismedencei k\u00f3rk\u00e9pek kezel\u00e9s\u00e9ben.] Orv Hetil. 2018; 159: 1735-1740. [Hungarian]","DOI":"10.1556\/650.2018.31228"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Romics M, Kiss G, Er\u0151ss L, et al. Preliminary experiences with sacral neuromodulation in the treatment of non-obstructive urinary retention. [Kezdeti tapasztalataink sacralis neuromodul\u00e1ci\u00f3val az idiopathi\u00e1s vizeletretenci\u00f3 kezel\u00e9s\u00e9ben.] Magy Urol. 2017; 29: 167-172. [Hungarian]","DOI":"10.22591\/magyurol.2017.4.romicsm.167"},{"key":"ref9","unstructured":"10 Dressler D. Basic principles of botulinum toxin therapy. In: Dressler D. (ed.) Botulinum toxin therapy. George Thieme Verlag, Stuttgart, New York, 2000; pp. 3-38."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"11 Dykstra","year":"1988","unstructured":"11 Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988; 139: 919-922.","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Schurch B, St\u00f6hrer M, Kramer G. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000; 164(3 Pt 1): 692-697.","DOI":"10.1016\/S0022-5347(05)67283-7"},{"key":"ref12","unstructured":"13 Majoros A, Pytel \u00c1, Bajory Z. The urinary incontinence. In: Pajor L. (ed.) Guidelines of urology in Hungary. [A vizeletinkontinencia. In: Pajor L. (szerk.) A magyar urol\u00f3gia ir\u00e1nyelvei.] Promenade Publishing House, Budapest, 2010; pp. 36-57. [Hungarian]"},{"key":"ref13","unstructured":"14 Majoros A, Hamvas A, Keszthelyi A, et al. Botulinum-A toxin (Dysport) therapy for therapy-resistant overactive bladder. [A botulinum A toxin (Dysport) alkalmaz\u00e1sa ter\u00e1piarezisztens hyperakt\u00edv h\u00f3lyagm\u0171k\u00f6d\u00e9s eset\u00e9n.] Magyar Kontinencia T\u00e1rsas\u00e1g I. Kongresszusa, Keszthely, 2005. november 24-26. Abstract. [Hungarian]"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 Majoros A, Romics M. Diagnosis and treatment of the overactive bladder. [A hiperakt\u00edv h\u00f3lyag kivizsg\u00e1l\u00e1sa \u00e9s kezel\u00e9se.] Lege Artis Med. 2020; 30: 131-136. [Hungarian]","DOI":"10.33616\/lam.30.013"},{"key":"ref15","unstructured":"16 Sipos A, Kov\u00e1cs \u00c1, Nyir\u00e1dy P, et al. Domestic practice of surgical treatment of female urinary incontinence and urogenital prolapse. [A n\u0151i vizeletinkontinencia \u00e9s urogenit\u00e1lis prolapszus seb\u00e9szi kezel\u00e9s\u00e9nek hazai gyakorlata.] Magy N\u0151orv L. 2015; 78: 38-45. [Hungarian]"},{"key":"ref16","unstructured":"17 Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2017; 197: S216-S223."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","article-title":"Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder","volume":"135","author":"18 Abrar","year":"2020","unstructured":"18 Abrar M, Stroman L, Malde S. Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder. Urology 2020; 135: 32-37.","journal-title":"Urology"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19 Pytel \u00c1. Percutaneous tibial nerve stimulation (PTNS) in the treatment of the overactive bladder syndrome: first Hungarian experiences. [A perkut\u00e1n nervus tibi\u00e1lis posterior stimul\u00e1ci\u00f3 (PTNS) a t\u00falm\u0171k\u00f6d\u0151 h\u00f3lyagszindr\u00f3ma kezel\u00e9s\u00e9ben: els\u0151 hazai tapasztalatok.] Magy Urol. 2018; 30: 65-68. [Hungarian]","DOI":"10.22591\/magyurol.2018.2.pytela.65"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00192-020-04427-w","article-title":"Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA","volume":"32","author":"20 He","year":"2021","unstructured":"20 He Q, Li B, Zhang C, et al. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA. Int Urogynecol J. 2021; 32: 477-484.","journal-title":"Int Urogynecol J"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/36\/article-p1459.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/36\/article-p1459.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:18:25Z","timestamp":1698657505000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/36\/article-p1459.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,5]]},"references-count":20,"journal-issue":{"issue":"36"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32288","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,5]]}}}